spacer gif spacer gif spacer gif spacer gif spacer gif
QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents    

First published online 11 April 2006
doi: 10.1242/jcs.02887

Journal of Cell Science 119, 1790-1800 (2006)
Published by The Company of Biologists 2006
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jcs.02887v1
119/9/1790    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Macotela, Y.
Right arrow Articles by Clapp, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Macotela, Y.
Right arrow Articles by Clapp, C.

Research Article

Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin

Yazmín Macotela1, Manuel B. Aguilar1, Jessica Guzmán-Morales1, José C. Rivera1, Consuelo Zermeño2, Fernando López-Barrera1, Gabriel Nava1, Carlos Lavalle3, Gonzalo Martínez de la Escalera1 and Carmen Clapp1,*

1 Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, México
2 Escuela Superior de Medicina, Instituto Politécnico Nacional, México DF, México
3 Hospital General "Xoco", Secretaría de Salud, Gobierno del Distrito Federal, México

* Author for correspondence (e-mail: clapp{at}servidor.unam.mx)

Accepted 12 January 2006

The 16 kDa N-terminal fragment of prolactin (16K-prolactin) is a potent antiangiogenic factor. Here, we demonstrate that matrix metalloproteases (MMPs) produced and secreted by chondrocytes generate biologically functional 16K-prolactin from full-length prolactin. When incubated with human prolactin at neutral pH, chondrocyte extracts and conditioned medium, as well as chondrocytes in culture, cleaved the Ser155-Leu156 peptide bond in prolactin, yielding - upon reduction of intramolecular disulfide bonds - a 16 kDa N-terminal fragment. This 16K-prolactin inhibited basic fibroblast growth factor (FGF)-induced endothelial cell proliferation in vitro. The Ser155-Leu156 site is highly conserved, and both human and rat prolactin were cleaved at this site by chondrocytes from either species. Conversion of prolactin to 16K-prolactin by chondrocyte lysates was completely abolished by the MMP inhibitors EDTA, GM6001 or 1,10-phenanthroline. Purified MMP-1, MMP-2, MMP-3, MMP-8, MMP-9 and MMP-13 cleaved human prolactin at Gln157, one residue downstream from the chondrocyte protease cleavage site, with the following relative potency: MMP-8>MMP-13 >MMP-3>MMP-1=MMP-2>MMP-9. Finally, chondrocytes expressed prolactin mRNA (as revealed by RT-PCR) and they contained and released antiangiogenic N-terminal 16 kDa prolactin (detected by western blot and endothelial cell proliferation). These results suggest that several matrix metalloproteases in cartilage generate antiangiogenic 16K-prolactin from systemically derived or locally produced prolactin.

Key words: Angiogenesis inhibitor, Matrix metalloproteinases, 16K-prolactin, Chondrocytes, Proteolytic processing




This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. Clapp, S. Thebault, E. Arnold, C. Garcia, J. C. Rivera, and G. M. de la Escalera
Vasoinhibins: novel inhibitors of ocular angiogenesis
Am J Physiol Endocrinol Metab, October 1, 2008; 295(4): E772 - E778.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
R. A. Dean, G. S. Butler, Y. Hamma-Kourbali, J. Delbe, D. R. Brigstock, J. Courty, and C. M. Overall
Identification of Candidate Angiogenic Inhibitors Processed by Matrix Metalloproteinase 2 (MMP-2) in Cell-Based Proteomic Screens: Disruption of Vascular Endothelial Growth Factor (VEGF)/Heparin Affin Regulatory Peptide (Pleiotrophin) and VEGF/Connective Tissue Growth Factor Angiogenic Inhibitory Complexes by MMP-2 Proteolysis
Mol. Cell. Biol., December 15, 2007; 27(24): 8454 - 8465.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S.-H. Lee, J. Kunz, S.-H. Lin, and L.-y. Yu-Lee
16-kDa Prolactin Inhibits Endothelial Cell Migration by Down-Regulating the Ras-Tiam1-Rac1-Pak1 Signaling Pathway
Cancer Res., November 15, 2007; 67(22): 11045 - 11053.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. Erdmann, A. Ricken, C. Merkwitz, I. Struman, R. Castino, K. Hummitzsch, F. Gaunitz, C. Isidoro, J. Martial, and K. Spanel-Borowski
The expression of prolactin and its cathepsin D-mediated cleavage in the bovine corpus luteum vary with the estrous cycle
Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1365 - E1377.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Ge, C. A. Fernandez, M. A. Moses, and D. S. Greenspan
Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor
PNAS, June 12, 2007; 104(24): 10010 - 10015.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
D. Piwnica, I. Fernandez, N. Binart, P. Touraine, P. A. Kelly, and V. Goffin
A New Mechanism for Prolactin Processing into 16K PRL by Secreted Cathepsin D
Mol. Endocrinol., December 1, 2006; 20(12): 3263 - 3278.
[Abstract] [Full Text] [PDF]


© The Company of Biologists Ltd 2006